Improvement of quality of life after ablation of longstanding persistent versus paroxysmal atrial fibrillation: results of 2-year follow-up

Česká verzia

Authors: V. Bulková ^1,2; M. Fiala ³; L. Haman ⁴; J. Chovančík ³; L. Škňouřil ³; Š. Havránek ¹; J. Pindor ³; J. Duda ⁴; J. Gorzolka ³; Kateřina Ivanová ² ; P. Pařízek ⁴
Authors place of work: II. interní klinika kardiologie a angiologie 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Aleš Linhart, DrSc. ¹; Ústav sociálního lékařství a zdravotní politiky Lékařské fakulty UP Olomouc, přednostka doc. PhDr. Kateřina Ivanová, Ph. D. ²; Oddělení kardiologie Nemocnice Podlesí, a. s., Třinec, přednosta prim. MUDr. Marian Branny ³; I. interní klinika Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MUDr. Jan Vojáček, DrSc. ⁴
Published in the journal: Vnitř Lék 2011; 57(5): 456-462
Category: Original Contributions

Summary

Aims:
The purpose of the study was to assess quality of life and socio-economic parameters in patients after ablation of paroxysmal versus longstanding persistent atrial fibrillation (AF).

Methods:
The study included 89 patients with paroxysmal AF and 56 patients with longstanding persistent AF who underwent ablation within 1 year, and were afterwards prospectively followed up for 2 years. Quality of life was evaluated by the EQ-5D questionnaire before and every 6 months after ablation.

Results:
Objective, respectively subjective quality of life at baseline was lower in patients with longstanding persistent AF (67 ± 16 vs 71 ± 10; p = 0.01, resp. 64 ± 12 vs 67 ± 16; p = 0.07); however, after 2 years, it exceeded that of the patients with paroxysmal AF (80 ± 17 vs 75 ± 18; p = 0.03; resp. 73 ± 13 vs 70 ± 17; p = 0.18). The baseline-2 year difference in improvement was higher in patients with longstanding persistent AF in both objective (p = 0,001) and subjective component (p = 0.05). Both groups displayed significant decrease in the days of hospitalization, and the days of working incapacity.

Conclusion:
Patients with longstanding persistent AF exhibit worse baseline quality of life than the patients with paroxysmal AF, and higher quality of life improvement after ablation.

Key words:
atrial fibrillation – paroxysmal atrial fibrillation – persistent atrial fibrillation – quality of life

Zdroje

1. Wokhlu A, Monahan KH, Hodge DO et al. Long-term quality of life after ablation of atrial fibrillation: the impact of recurrence, symptom relief, and placebo effect. J Am Coll Cardiol 2010; 55: 2309–2316.

2. Chan PS, Vijan S, Morady F et al. Cost-effectiveness of radiofrequency catheter ablation for atrial fibrillation. J Am Coll Cardiol 2006; 47: 2513–2520.

3. Wazni OM, Marrouche NF, Martin DO et al. Radiofrequency ablation vs. Antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005; 293: 2634–2640.

4. Jaïs P, Cauchemez B, Macle L et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation 2008; 118: 2498–2505.

5. Wilber DJ, Pappone C, Neuzil P et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: A randomized controlled trial. JAMA 2010; 303: 333–340.

6. Packer DL, Bardy GH, Worley SJ et al. Tachycardia-induced cardiomaopathy: a reversible form of left ventricular dysfunction. Am J Cardiol 1986; 57: 563–570.

7. Lévy S, Maarek M, Coumel P et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation 1999; 99: 3028–3035.

8. Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. N Eng J Med 1979; 300: 1350–1358.